INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24601, 0, 'Saquinavir', 'Kidney Diseases', 'The principal route of excretion for saquinavir is by hepatic metabolism, therefore no initial dose adjustment is necessary in patients with renal impairment.  However, saquinavir has not been studied in patients with severe renal impairment and end-stage renal disease, and caution should be exercised when prescribing this drug to these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24602, 0, 'Sarecycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24603, 0, 'Sarecycline', 'Liver Failure', 'The effect of end-stage renal disease (ESRD) or severe hepatic impairment (Child-Pugh C) on sarecycline pharmacokinetics has not been assessed.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24604, 0, 'Scopolamine (ophthalmic)', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24605, 0, 'Scopolamine', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24606, 0, 'Scopolamine', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24607, 0, 'Scopolamine', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24608, 0, 'Scopolamine', 'Urinary Bladder Neck Obstruction', 'In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy.  Dysuria may occur and may require catheterization.  Also, anticholinergic drugs may aggravate partial obstructive uropathy.  Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24609, 0, 'Scopolamine', 'Lung Diseases', 'The use of systemic anticholinergics is contraindicated in the treatment of lower respiratory tract symptoms including asthma.  Muscarinic receptor antagonists reduce bronchial secretions, which can result in decreased fluidity and increased thickening of secretions.  However, ipratropium does not produce these effects and can be used safely in treating asthma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24610, 0, 'Scopolamine', 'Myasthenia Gravis', 'Because antimuscarinic agents have anticholinergic effects, they are contraindicated in patients with myasthenia gravis.  Their use may be appropriate to reduce adverse muscarinic effects caused by an anticholinesterase agent.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24611, 0, 'Scopolamine', 'Dysentery', 'The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria.  These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool.  Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24612, 0, 'Scopolamine', 'Heart Diseases', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously to patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization, ventricular tachycardia, and fibrillation associated with anticholinergics are rare.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24613, 0, 'Scopolamine', 'Tachycardia', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously in patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization or ventricular tachycardia or fibrillation associated with anticholinergics is rare.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24614, 0, 'Scopolamine', 'Coronary Artery Disease', 'Antimuscarinic agents block vagal inhibition of the SA nodal pacemaker.  These agents should be administered cautiously in patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization or ventricular tachycardia or fibrillation associated with antimuscarinic drugs is rare.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24615, 0, 'Scopolamine', 'Stomach Ulcer', 'Antimuscarinic agents may cause a delay in gastric emptying and possibly antral stasis in patients with gastric ulcer.  Therapy with antimuscarinic agents should be administered cautiously to patients with gastric ulcer.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24616, 0, 'Scopolamine', 'Gastroesophageal Reflux', 'Antimuscarinic agents decrease gastric motility and relax the lower esophageal sphincter which promotes gastric retention and can aggravate reflux.  These drugs should be administered cautiously in patients with gastroesophageal reflux or hiatal hernia associated with reflux esophagitis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24617, 0, 'Scopolamine', 'Colitis, Ulcerative', 'Antimuscarinic agents may suppress intestinal motility and produce paralytic ileus with resultant precipitation of toxic megacolon.  These drugs should be administered cautiously to patients with ulcerative colitis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24618, 0, 'Scopolamine', 'Hypertension', 'Cardiovascular effects of anticholinergics may exacerbate hypertension.  Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24619, 0, 'Scopolamine', 'Hyperthyroidism', 'In general, agents with anticholinergic activity may exacerbate hyperthyroidism.  Therapy with anticholinergics should be administered cautiously in patients with hyperthyroidism.  Thyroid levels should be monitored if usage is prolonged.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24620, 0, 'Scopolamine', 'Diarrhea', 'Diarrhea may be a symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy.  Antimuscarinic agents may further aggravate the diarrhea.  Therefore, these drugs should be administered cautiously in patients with diarrhea.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24621, 0, 'Scopolamine', 'Fever', 'Atropine-like agents may increase the risk of hyperthermia in patients with fever by producing anhidrosis.  Therapy with atropine-like agents should be administered cautiously in febrile patients.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24622, 9267, 'Saxagliptin', 'Pancreatitis', 'There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors.  These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk.  Patients should be observed for signs and symptoms of pancreatitis during treatment.  If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24623, 19331, 'Saxagliptin', 'Pancreatitis', 'There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors.  These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk.  Patients should be observed for signs and symptoms of pancreatitis during treatment.  If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24624, 24125, 'Saxagliptin', 'Pancreatitis', 'There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors.  These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk.  Patients should be observed for signs and symptoms of pancreatitis during treatment.  If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24625, 26571, 'Saxagliptin', 'Pancreatitis', 'There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors.  These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk.  Patients should be observed for signs and symptoms of pancreatitis during treatment.  If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24626, 9267, 'Saxagliptin', 'Kidney Diseases', 'It is recommended to assess renal function prior to initiating treatment with DPP-4 inhibitors.  Patients with moderate to severe renal insufficiency and end stage renal dysfunction will require a dose adjustment.  Linagliptin will not require a dose adjustment per manufacturer''s information.  Additionally, there have been postmarketing reports of worsening renal function in some patients with renal insufficiency taking sitagliptin at inappropriate doses.  However, sitagliptin has not been found to be nephrotoxic in preclinical studies or clinical trials at appropriate doses.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24627, 19331, 'Saxagliptin', 'Kidney Diseases', 'It is recommended to assess renal function prior to initiating treatment with DPP-4 inhibitors.  Patients with moderate to severe renal insufficiency and end stage renal dysfunction will require a dose adjustment.  Linagliptin will not require a dose adjustment per manufacturer''s information.  Additionally, there have been postmarketing reports of worsening renal function in some patients with renal insufficiency taking sitagliptin at inappropriate doses.  However, sitagliptin has not been found to be nephrotoxic in preclinical studies or clinical trials at appropriate doses.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24628, 24125, 'Saxagliptin', 'Kidney Diseases', 'It is recommended to assess renal function prior to initiating treatment with DPP-4 inhibitors.  Patients with moderate to severe renal insufficiency and end stage renal dysfunction will require a dose adjustment.  Linagliptin will not require a dose adjustment per manufacturer''s information.  Additionally, there have been postmarketing reports of worsening renal function in some patients with renal insufficiency taking sitagliptin at inappropriate doses.  However, sitagliptin has not been found to be nephrotoxic in preclinical studies or clinical trials at appropriate doses.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24629, 26571, 'Saxagliptin', 'Kidney Diseases', 'It is recommended to assess renal function prior to initiating treatment with DPP-4 inhibitors.  Patients with moderate to severe renal insufficiency and end stage renal dysfunction will require a dose adjustment.  Linagliptin will not require a dose adjustment per manufacturer''s information.  Additionally, there have been postmarketing reports of worsening renal function in some patients with renal insufficiency taking sitagliptin at inappropriate doses.  However, sitagliptin has not been found to be nephrotoxic in preclinical studies or clinical trials at appropriate doses.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24630, 515, 'Secnidazole', 'Cockayne Syndrome', 'Secnidazole is contraindicated in patients with Cockayne syndrome.  Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after start of metronidazole (another nitroimidazole drug structurally related to secnidazole) in patients with Cockayne syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24631, 2607, 'Secnidazole', 'Cockayne Syndrome', 'Secnidazole is contraindicated in patients with Cockayne syndrome.  Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after start of metronidazole (another nitroimidazole drug structurally related to secnidazole) in patients with Cockayne syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24632, 4487, 'Secnidazole', 'Cockayne Syndrome', 'Secnidazole is contraindicated in patients with Cockayne syndrome.  Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after start of metronidazole (another nitroimidazole drug structurally related to secnidazole) in patients with Cockayne syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24633, 4895, 'Secnidazole', 'Cockayne Syndrome', 'Secnidazole is contraindicated in patients with Cockayne syndrome.  Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after start of metronidazole (another nitroimidazole drug structurally related to secnidazole) in patients with Cockayne syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24634, 10238, 'Secnidazole', 'Cockayne Syndrome', 'Secnidazole is contraindicated in patients with Cockayne syndrome.  Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after start of metronidazole (another nitroimidazole drug structurally related to secnidazole) in patients with Cockayne syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24635, 10239, 'Secnidazole', 'Cockayne Syndrome', 'Secnidazole is contraindicated in patients with Cockayne syndrome.  Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after start of metronidazole (another nitroimidazole drug structurally related to secnidazole) in patients with Cockayne syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24636, 19073, 'Secnidazole', 'Cockayne Syndrome', 'Secnidazole is contraindicated in patients with Cockayne syndrome.  Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after start of metronidazole (another nitroimidazole drug structurally related to secnidazole) in patients with Cockayne syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24637, 19074, 'Secnidazole', 'Cockayne Syndrome', 'Secnidazole is contraindicated in patients with Cockayne syndrome.  Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after start of metronidazole (another nitroimidazole drug structurally related to secnidazole) in patients with Cockayne syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24638, 24146, 'Secnidazole', 'Cockayne Syndrome', 'Secnidazole is contraindicated in patients with Cockayne syndrome.  Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after start of metronidazole (another nitroimidazole drug structurally related to secnidazole) in patients with Cockayne syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24639, 26659, 'Secnidazole', 'Cockayne Syndrome', 'Secnidazole is contraindicated in patients with Cockayne syndrome.  Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after start of metronidazole (another nitroimidazole drug structurally related to secnidazole) in patients with Cockayne syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24640, 26763, 'Secnidazole', 'Cockayne Syndrome', 'Secnidazole is contraindicated in patients with Cockayne syndrome.  Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after start of metronidazole (another nitroimidazole drug structurally related to secnidazole) in patients with Cockayne syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24641, 515, 'Secnidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24642, 2607, 'Secnidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24643, 4487, 'Secnidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24644, 4895, 'Secnidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24645, 10238, 'Secnidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24646, 10239, 'Secnidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24647, 19073, 'Secnidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24648, 19074, 'Secnidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24649, 24146, 'Secnidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24650, 26659, 'Secnidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24651, 26763, 'Secnidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24652, 24582, 'Selegiline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24653, 28283, 'Selegiline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24654, 28428, 'Selegiline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24655, 24582, 'Selegiline', 'Psychotic Disorders', 'Patients with major psychotic disorders should ordinarily not be treated with selegiline because of the risk of exacerbating psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24656, 28283, 'Selegiline', 'Psychotic Disorders', 'Patients with major psychotic disorders should ordinarily not be treated with selegiline because of the risk of exacerbating psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24657, 28428, 'Selegiline', 'Psychotic Disorders', 'Patients with major psychotic disorders should ordinarily not be treated with selegiline because of the risk of exacerbating psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24658, 24582, 'Selegiline', 'Kidney Failure, Chronic', 'Small increments in serum BUN and creatinine have been observed in patients treated with high dose of selegiline.  Treatment with selegiline is not recommended in patients with severe renal impairment and end-stage renal disease (CrCl <30 mL/min).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24659, 28283, 'Selegiline', 'Kidney Failure, Chronic', 'Small increments in serum BUN and creatinine have been observed in patients treated with high dose of selegiline.  Treatment with selegiline is not recommended in patients with severe renal impairment and end-stage renal disease (CrCl <30 mL/min).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24660, 28428, 'Selegiline', 'Kidney Failure, Chronic', 'Small increments in serum BUN and creatinine have been observed in patients treated with high dose of selegiline.  Treatment with selegiline is not recommended in patients with severe renal impairment and end-stage renal disease (CrCl <30 mL/min).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24661, 24582, 'Selegiline', 'Heart Diseases', 'The use of selegiline has been associated with cardiovascular events such as tachycardia, bradycardia, syncope, hypertension, hypotension, arrhythmias, and aggravation of angina pectoris.  Therapy with selegiline should be administered cautiously in patients with cardiac disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24662, 28283, 'Selegiline', 'Heart Diseases', 'The use of selegiline has been associated with cardiovascular events such as tachycardia, bradycardia, syncope, hypertension, hypotension, arrhythmias, and aggravation of angina pectoris.  Therapy with selegiline should be administered cautiously in patients with cardiac disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24663, 28428, 'Selegiline', 'Heart Diseases', 'The use of selegiline has been associated with cardiovascular events such as tachycardia, bradycardia, syncope, hypertension, hypotension, arrhythmias, and aggravation of angina pectoris.  Therapy with selegiline should be administered cautiously in patients with cardiac disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24664, 24582, 'Selegiline', 'Glaucoma', 'The use of selegiline may exacerbate glaucoma.  Therapy with selegiline should be administered cautiously in patients with glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24665, 28283, 'Selegiline', 'Glaucoma', 'The use of selegiline may exacerbate glaucoma.  Therapy with selegiline should be administered cautiously in patients with glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24666, 28428, 'Selegiline', 'Glaucoma', 'The use of selegiline may exacerbate glaucoma.  Therapy with selegiline should be administered cautiously in patients with glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24667, 24582, 'Selegiline', 'Hypertension', 'Selegiline can cause hypertensive reactions and it should be used with caution in patients with hypertension.  Patients should report any symptoms such as occipital headache, palpitations, neck stiffness or soreness, nausea, sweating, dilated pupils and photophobia.  Patients receiving therapy need to have monitored their blood pressure frequently to detect any evidence of pressor response.  Additionally, patients should be advised to avoid foods and drinks with high tyramine content such as cheese, sour cream, beer, liver, bananas and others, as these might trigger a hypertensive crisis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24668, 28283, 'Selegiline', 'Hypertension', 'Selegiline can cause hypertensive reactions and it should be used with caution in patients with hypertension.  Patients should report any symptoms such as occipital headache, palpitations, neck stiffness or soreness, nausea, sweating, dilated pupils and photophobia.  Patients receiving therapy need to have monitored their blood pressure frequently to detect any evidence of pressor response.  Additionally, patients should be advised to avoid foods and drinks with high tyramine content such as cheese, sour cream, beer, liver, bananas and others, as these might trigger a hypertensive crisis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24669, 28428, 'Selegiline', 'Hypertension', 'Selegiline can cause hypertensive reactions and it should be used with caution in patients with hypertension.  Patients should report any symptoms such as occipital headache, palpitations, neck stiffness or soreness, nausea, sweating, dilated pupils and photophobia.  Patients receiving therapy need to have monitored their blood pressure frequently to detect any evidence of pressor response.  Additionally, patients should be advised to avoid foods and drinks with high tyramine content such as cheese, sour cream, beer, liver, bananas and others, as these might trigger a hypertensive crisis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24670, 24582, 'Selegiline', 'Liver Diseases', 'Patients with mild to moderate hepatic impairment (Child-Pugh 5 to 9), may require a dose reduction of selegiline depending on their clinical response.  Selegiline is not recommended in patients with severe hepatic impairment (Child-Pugh >9).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24671, 28283, 'Selegiline', 'Liver Diseases', 'Patients with mild to moderate hepatic impairment (Child-Pugh 5 to 9), may require a dose reduction of selegiline depending on their clinical response.  Selegiline is not recommended in patients with severe hepatic impairment (Child-Pugh >9).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24672, 28428, 'Selegiline', 'Liver Diseases', 'Patients with mild to moderate hepatic impairment (Child-Pugh 5 to 9), may require a dose reduction of selegiline depending on their clinical response.  Selegiline is not recommended in patients with severe hepatic impairment (Child-Pugh >9).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24673, 24582, 'Selegiline', 'Melanoma', 'Patients with Parkinson''s disease have a higher risk of developing melanoma than the general population.  Patients and providers should be advised to monitor for melanoma frequently and regularly when using selegiline.  Skin examinations should be performed by qualified individuals (e.g., dermatologists).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24674, 28283, 'Selegiline', 'Melanoma', 'Patients with Parkinson''s disease have a higher risk of developing melanoma than the general population.  Patients and providers should be advised to monitor for melanoma frequently and regularly when using selegiline.  Skin examinations should be performed by qualified individuals (e.g., dermatologists).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24675, 28428, 'Selegiline', 'Melanoma', 'Patients with Parkinson''s disease have a higher risk of developing melanoma than the general population.  Patients and providers should be advised to monitor for melanoma frequently and regularly when using selegiline.  Skin examinations should be performed by qualified individuals (e.g., dermatologists).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24676, 24582, 'Selegiline', 'Sleep Wake Disorders', 'Selegiline should be used with caution in patients with sleep disorders as it can cause somnolence.  Patients should exercise caution when driving, operating machines, or working at heights during treatment.  Treatment should be discontinued if patients develop daytime sleepiness with episodes of falling asleep during activities such as conversation, eating, etc.  If not discontinued, patients should be very cautious about the activities that they engage in that could be potentially dangerous.  Prescribers should question the patients specifically about somnolence, as it is rarely reported by patients, and ask about sleep disorders and the use of concomitant sedating medications.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24677, 28283, 'Selegiline', 'Sleep Wake Disorders', 'Selegiline should be used with caution in patients with sleep disorders as it can cause somnolence.  Patients should exercise caution when driving, operating machines, or working at heights during treatment.  Treatment should be discontinued if patients develop daytime sleepiness with episodes of falling asleep during activities such as conversation, eating, etc.  If not discontinued, patients should be very cautious about the activities that they engage in that could be potentially dangerous.  Prescribers should question the patients specifically about somnolence, as it is rarely reported by patients, and ask about sleep disorders and the use of concomitant sedating medications.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24678, 28428, 'Selegiline', 'Sleep Wake Disorders', 'Selegiline should be used with caution in patients with sleep disorders as it can cause somnolence.  Patients should exercise caution when driving, operating machines, or working at heights during treatment.  Treatment should be discontinued if patients develop daytime sleepiness with episodes of falling asleep during activities such as conversation, eating, etc.  If not discontinued, patients should be very cautious about the activities that they engage in that could be potentially dangerous.  Prescribers should question the patients specifically about somnolence, as it is rarely reported by patients, and ask about sleep disorders and the use of concomitant sedating medications.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24679, 24582, 'Selegiline', 'Urinary Retention', 'The use of selegiline may exacerbate urinary retention.  Therapy with selegiline should be administered cautiously in patients with urinary retention or obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24680, 28283, 'Selegiline', 'Urinary Retention', 'The use of selegiline may exacerbate urinary retention.  Therapy with selegiline should be administered cautiously in patients with urinary retention or obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24681, 28428, 'Selegiline', 'Urinary Retention', 'The use of selegiline may exacerbate urinary retention.  Therapy with selegiline should be administered cautiously in patients with urinary retention or obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24682, 281, 'Baricitinib', 'Infections', 'Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in rheumatoid arthritis patients receiving baricitinib; the most common serious infections reported included pneumonia, herpes zoster, and urinary tract infection.  Use of baricitinib should be avoided in patients with an active, serious infection, including localized infections.  The risks and benefits of treatment should be considered before starting baricitinib in patients:  with chronic/recurrent infection, who have been exposed to tuberculosis, with history of serious/opportunistic infection, who have resided/traveled in areas of endemic tuberculosis/mycoses, or with underlying conditions that may predispose them to infection.  Patients with rheumatoid arthritis or alopecia areata should be closely monitored for signs/symptoms of infection during and after baricitinib treatment.  Baricitinib should be interrupted in patients with rheumatoid arthritis or alopecia areata if a serious infection, an opportunistic infection, or sepsis develops.  A patient who develops a new infection during treatment with baricitinib should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient; appropriate antimicrobial therapy should be started, the patient should be monitored closely, and baricitinib should be interrupted if the patient is not responding to therapy.  Baricitinib should not be resumed until the infection is controlled.Patients with coronavirus disease 2019 (COVID-19) should be monitored for signs/symptoms of new infections during and after baricitinib treatment.  The risks and benefits of baricitinib in COVID-19 patients with other concomitant infections should be considered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24683, 24035, 'Baricitinib', 'Infections', 'Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in rheumatoid arthritis patients receiving baricitinib; the most common serious infections reported included pneumonia, herpes zoster, and urinary tract infection.  Use of baricitinib should be avoided in patients with an active, serious infection, including localized infections.  The risks and benefits of treatment should be considered before starting baricitinib in patients:  with chronic/recurrent infection, who have been exposed to tuberculosis, with history of serious/opportunistic infection, who have resided/traveled in areas of endemic tuberculosis/mycoses, or with underlying conditions that may predispose them to infection.  Patients with rheumatoid arthritis or alopecia areata should be closely monitored for signs/symptoms of infection during and after baricitinib treatment.  Baricitinib should be interrupted in patients with rheumatoid arthritis or alopecia areata if a serious infection, an opportunistic infection, or sepsis develops.  A patient who develops a new infection during treatment with baricitinib should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient; appropriate antimicrobial therapy should be started, the patient should be monitored closely, and baricitinib should be interrupted if the patient is not responding to therapy.  Baricitinib should not be resumed until the infection is controlled.Patients with coronavirus disease 2019 (COVID-19) should be monitored for signs/symptoms of new infections during and after baricitinib treatment.  The risks and benefits of baricitinib in COVID-19 patients with other concomitant infections should be considered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24684, 24036, 'Baricitinib', 'Infections', 'Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in rheumatoid arthritis patients receiving baricitinib; the most common serious infections reported included pneumonia, herpes zoster, and urinary tract infection.  Use of baricitinib should be avoided in patients with an active, serious infection, including localized infections.  The risks and benefits of treatment should be considered before starting baricitinib in patients:  with chronic/recurrent infection, who have been exposed to tuberculosis, with history of serious/opportunistic infection, who have resided/traveled in areas of endemic tuberculosis/mycoses, or with underlying conditions that may predispose them to infection.  Patients with rheumatoid arthritis or alopecia areata should be closely monitored for signs/symptoms of infection during and after baricitinib treatment.  Baricitinib should be interrupted in patients with rheumatoid arthritis or alopecia areata if a serious infection, an opportunistic infection, or sepsis develops.  A patient who develops a new infection during treatment with baricitinib should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient; appropriate antimicrobial therapy should be started, the patient should be monitored closely, and baricitinib should be interrupted if the patient is not responding to therapy.  Baricitinib should not be resumed until the infection is controlled.Patients with coronavirus disease 2019 (COVID-19) should be monitored for signs/symptoms of new infections during and after baricitinib treatment.  The risks and benefits of baricitinib in COVID-19 patients with other concomitant infections should be considered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24685, 31767, 'Baricitinib', 'Infections', 'Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in rheumatoid arthritis patients receiving baricitinib; the most common serious infections reported included pneumonia, herpes zoster, and urinary tract infection.  Use of baricitinib should be avoided in patients with an active, serious infection, including localized infections.  The risks and benefits of treatment should be considered before starting baricitinib in patients:  with chronic/recurrent infection, who have been exposed to tuberculosis, with history of serious/opportunistic infection, who have resided/traveled in areas of endemic tuberculosis/mycoses, or with underlying conditions that may predispose them to infection.  Patients with rheumatoid arthritis or alopecia areata should be closely monitored for signs/symptoms of infection during and after baricitinib treatment.  Baricitinib should be interrupted in patients with rheumatoid arthritis or alopecia areata if a serious infection, an opportunistic infection, or sepsis develops.  A patient who develops a new infection during treatment with baricitinib should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient; appropriate antimicrobial therapy should be started, the patient should be monitored closely, and baricitinib should be interrupted if the patient is not responding to therapy.  Baricitinib should not be resumed until the infection is controlled.Patients with coronavirus disease 2019 (COVID-19) should be monitored for signs/symptoms of new infections during and after baricitinib treatment.  The risks and benefits of baricitinib in COVID-19 patients with other concomitant infections should be considered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24686, 31792, 'Baricitinib', 'Infections', 'Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in rheumatoid arthritis patients receiving baricitinib; the most common serious infections reported included pneumonia, herpes zoster, and urinary tract infection.  Use of baricitinib should be avoided in patients with an active, serious infection, including localized infections.  The risks and benefits of treatment should be considered before starting baricitinib in patients:  with chronic/recurrent infection, who have been exposed to tuberculosis, with history of serious/opportunistic infection, who have resided/traveled in areas of endemic tuberculosis/mycoses, or with underlying conditions that may predispose them to infection.  Patients with rheumatoid arthritis or alopecia areata should be closely monitored for signs/symptoms of infection during and after baricitinib treatment.  Baricitinib should be interrupted in patients with rheumatoid arthritis or alopecia areata if a serious infection, an opportunistic infection, or sepsis develops.  A patient who develops a new infection during treatment with baricitinib should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient; appropriate antimicrobial therapy should be started, the patient should be monitored closely, and baricitinib should be interrupted if the patient is not responding to therapy.  Baricitinib should not be resumed until the infection is controlled.Patients with coronavirus disease 2019 (COVID-19) should be monitored for signs/symptoms of new infections during and after baricitinib treatment.  The risks and benefits of baricitinib in COVID-19 patients with other concomitant infections should be considered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24687, 281, 'Baricitinib', 'Tuberculosis', 'Baricitinib should not be given to patients with active tuberculosis (TB); patients should be evaluated for active infection before administering this agent.  Patients (except those with coronavirus disease 2019 [COVID-19]) should be tested for latent TB before starting baricitinib and during therapy; if positive, patients should be treated with standard antimycobacterial therapy before starting baricitinib.  Anti-TB therapy should be considered prior to initiating treatment with baricitinib in patients with history of latent/active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but who have risk factors for TB infection.  Consultation with a physician with expertise in the treatment of TB is recommended to aid in the decision about whether initiating anti-TB therapy is appropriate for an individual patient.  During baricitinib use, patients should be monitored for signs/symptoms of TB, including patients who tested negative for latent TB infection prior to initiating therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24688, 24035, 'Baricitinib', 'Tuberculosis', 'Baricitinib should not be given to patients with active tuberculosis (TB); patients should be evaluated for active infection before administering this agent.  Patients (except those with coronavirus disease 2019 [COVID-19]) should be tested for latent TB before starting baricitinib and during therapy; if positive, patients should be treated with standard antimycobacterial therapy before starting baricitinib.  Anti-TB therapy should be considered prior to initiating treatment with baricitinib in patients with history of latent/active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but who have risk factors for TB infection.  Consultation with a physician with expertise in the treatment of TB is recommended to aid in the decision about whether initiating anti-TB therapy is appropriate for an individual patient.  During baricitinib use, patients should be monitored for signs/symptoms of TB, including patients who tested negative for latent TB infection prior to initiating therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24689, 24036, 'Baricitinib', 'Tuberculosis', 'Baricitinib should not be given to patients with active tuberculosis (TB); patients should be evaluated for active infection before administering this agent.  Patients (except those with coronavirus disease 2019 [COVID-19]) should be tested for latent TB before starting baricitinib and during therapy; if positive, patients should be treated with standard antimycobacterial therapy before starting baricitinib.  Anti-TB therapy should be considered prior to initiating treatment with baricitinib in patients with history of latent/active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but who have risk factors for TB infection.  Consultation with a physician with expertise in the treatment of TB is recommended to aid in the decision about whether initiating anti-TB therapy is appropriate for an individual patient.  During baricitinib use, patients should be monitored for signs/symptoms of TB, including patients who tested negative for latent TB infection prior to initiating therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24690, 31767, 'Baricitinib', 'Tuberculosis', 'Baricitinib should not be given to patients with active tuberculosis (TB); patients should be evaluated for active infection before administering this agent.  Patients (except those with coronavirus disease 2019 [COVID-19]) should be tested for latent TB before starting baricitinib and during therapy; if positive, patients should be treated with standard antimycobacterial therapy before starting baricitinib.  Anti-TB therapy should be considered prior to initiating treatment with baricitinib in patients with history of latent/active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but who have risk factors for TB infection.  Consultation with a physician with expertise in the treatment of TB is recommended to aid in the decision about whether initiating anti-TB therapy is appropriate for an individual patient.  During baricitinib use, patients should be monitored for signs/symptoms of TB, including patients who tested negative for latent TB infection prior to initiating therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24691, 31792, 'Baricitinib', 'Tuberculosis', 'Baricitinib should not be given to patients with active tuberculosis (TB); patients should be evaluated for active infection before administering this agent.  Patients (except those with coronavirus disease 2019 [COVID-19]) should be tested for latent TB before starting baricitinib and during therapy; if positive, patients should be treated with standard antimycobacterial therapy before starting baricitinib.  Anti-TB therapy should be considered prior to initiating treatment with baricitinib in patients with history of latent/active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but who have risk factors for TB infection.  Consultation with a physician with expertise in the treatment of TB is recommended to aid in the decision about whether initiating anti-TB therapy is appropriate for an individual patient.  During baricitinib use, patients should be monitored for signs/symptoms of TB, including patients who tested negative for latent TB infection prior to initiating therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24692, 281, 'Baricitinib', 'Cardiovascular Diseases', 'In a major safety study of a Janus kinase (JAK) inhibitor, tofacitinib, in rheumatoid arthritis patients 50 years and older with at least 1 cardiovascular risk factor, higher rates of all-cause mortality (including sudden cardiovascular death) and major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke) were observed with the JAK inhibitor when compared with tumor necrosis factor (TNF) blockers; patients who are current or past smokers are at additional increased risk.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including baricitinib, upadacitinib, ruxolitinib, fedratinib, and pacritinib.  Before starting or continuing therapy, the benefits and risks for the individual patient should be considered, especially in patients with other cardiovascular risk factors and patients who are current or past smokers.  Patients should be informed about the symptoms of serious cardiovascular events and what to do if they occur.  Tofacitinib, baricitinib, and upadacitinib are indicated for patients with inadequate response or intolerance to 1 or more TNF blockers, but should be discontinued in patients who have experienced a myocardial infarction or stroke.  The dosage recommended for tofacitinib should not be exceeded; for the treatment of ulcerative colitis, tofacitinib should be used at the lowest effective dose and for the shortest duration needed to achieve and/or maintain therapeutic response.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24693, 24035, 'Baricitinib', 'Cardiovascular Diseases', 'In a major safety study of a Janus kinase (JAK) inhibitor, tofacitinib, in rheumatoid arthritis patients 50 years and older with at least 1 cardiovascular risk factor, higher rates of all-cause mortality (including sudden cardiovascular death) and major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke) were observed with the JAK inhibitor when compared with tumor necrosis factor (TNF) blockers; patients who are current or past smokers are at additional increased risk.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including baricitinib, upadacitinib, ruxolitinib, fedratinib, and pacritinib.  Before starting or continuing therapy, the benefits and risks for the individual patient should be considered, especially in patients with other cardiovascular risk factors and patients who are current or past smokers.  Patients should be informed about the symptoms of serious cardiovascular events and what to do if they occur.  Tofacitinib, baricitinib, and upadacitinib are indicated for patients with inadequate response or intolerance to 1 or more TNF blockers, but should be discontinued in patients who have experienced a myocardial infarction or stroke.  The dosage recommended for tofacitinib should not be exceeded; for the treatment of ulcerative colitis, tofacitinib should be used at the lowest effective dose and for the shortest duration needed to achieve and/or maintain therapeutic response.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24694, 24036, 'Baricitinib', 'Cardiovascular Diseases', 'In a major safety study of a Janus kinase (JAK) inhibitor, tofacitinib, in rheumatoid arthritis patients 50 years and older with at least 1 cardiovascular risk factor, higher rates of all-cause mortality (including sudden cardiovascular death) and major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke) were observed with the JAK inhibitor when compared with tumor necrosis factor (TNF) blockers; patients who are current or past smokers are at additional increased risk.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including baricitinib, upadacitinib, ruxolitinib, fedratinib, and pacritinib.  Before starting or continuing therapy, the benefits and risks for the individual patient should be considered, especially in patients with other cardiovascular risk factors and patients who are current or past smokers.  Patients should be informed about the symptoms of serious cardiovascular events and what to do if they occur.  Tofacitinib, baricitinib, and upadacitinib are indicated for patients with inadequate response or intolerance to 1 or more TNF blockers, but should be discontinued in patients who have experienced a myocardial infarction or stroke.  The dosage recommended for tofacitinib should not be exceeded; for the treatment of ulcerative colitis, tofacitinib should be used at the lowest effective dose and for the shortest duration needed to achieve and/or maintain therapeutic response.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24695, 31767, 'Baricitinib', 'Cardiovascular Diseases', 'In a major safety study of a Janus kinase (JAK) inhibitor, tofacitinib, in rheumatoid arthritis patients 50 years and older with at least 1 cardiovascular risk factor, higher rates of all-cause mortality (including sudden cardiovascular death) and major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke) were observed with the JAK inhibitor when compared with tumor necrosis factor (TNF) blockers; patients who are current or past smokers are at additional increased risk.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including baricitinib, upadacitinib, ruxolitinib, fedratinib, and pacritinib.  Before starting or continuing therapy, the benefits and risks for the individual patient should be considered, especially in patients with other cardiovascular risk factors and patients who are current or past smokers.  Patients should be informed about the symptoms of serious cardiovascular events and what to do if they occur.  Tofacitinib, baricitinib, and upadacitinib are indicated for patients with inadequate response or intolerance to 1 or more TNF blockers, but should be discontinued in patients who have experienced a myocardial infarction or stroke.  The dosage recommended for tofacitinib should not be exceeded; for the treatment of ulcerative colitis, tofacitinib should be used at the lowest effective dose and for the shortest duration needed to achieve and/or maintain therapeutic response.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24696, 31792, 'Baricitinib', 'Cardiovascular Diseases', 'In a major safety study of a Janus kinase (JAK) inhibitor, tofacitinib, in rheumatoid arthritis patients 50 years and older with at least 1 cardiovascular risk factor, higher rates of all-cause mortality (including sudden cardiovascular death) and major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke) were observed with the JAK inhibitor when compared with tumor necrosis factor (TNF) blockers; patients who are current or past smokers are at additional increased risk.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including baricitinib, upadacitinib, ruxolitinib, fedratinib, and pacritinib.  Before starting or continuing therapy, the benefits and risks for the individual patient should be considered, especially in patients with other cardiovascular risk factors and patients who are current or past smokers.  Patients should be informed about the symptoms of serious cardiovascular events and what to do if they occur.  Tofacitinib, baricitinib, and upadacitinib are indicated for patients with inadequate response or intolerance to 1 or more TNF blockers, but should be discontinued in patients who have experienced a myocardial infarction or stroke.  The dosage recommended for tofacitinib should not be exceeded; for the treatment of ulcerative colitis, tofacitinib should be used at the lowest effective dose and for the shortest duration needed to achieve and/or maintain therapeutic response.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24697, 281, 'Baricitinib', 'Neoplasms', 'Malignancies (including lymphomas and solid tumors) have been reported in patients treated with tofacitinib and other Janus kinase (JAK) inhibitors used to treat inflammatory conditions; lymphomas and other malignancies have been seen in patients treated with baricitinib or upadacitinib.  Patients who are current or past smokers are at additional increased risk of malignancies.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including ruxolitinib, pacritinib, and fedratinib.  Before starting or continuing therapy, the benefits and risks for the individual patient should be considered, especially in patients with a known malignancy (other than successfully treated nonmelanoma skin cancer), patients who develop a malignancy during therapy, and patients who are current or past smokers.  Periodic skin examination is recommended for patients who are at increased risk for skin cancer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24698, 24035, 'Baricitinib', 'Neoplasms', 'Malignancies (including lymphomas and solid tumors) have been reported in patients treated with tofacitinib and other Janus kinase (JAK) inhibitors used to treat inflammatory conditions; lymphomas and other malignancies have been seen in patients treated with baricitinib or upadacitinib.  Patients who are current or past smokers are at additional increased risk of malignancies.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including ruxolitinib, pacritinib, and fedratinib.  Before starting or continuing therapy, the benefits and risks for the individual patient should be considered, especially in patients with a known malignancy (other than successfully treated nonmelanoma skin cancer), patients who develop a malignancy during therapy, and patients who are current or past smokers.  Periodic skin examination is recommended for patients who are at increased risk for skin cancer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24699, 24036, 'Baricitinib', 'Neoplasms', 'Malignancies (including lymphomas and solid tumors) have been reported in patients treated with tofacitinib and other Janus kinase (JAK) inhibitors used to treat inflammatory conditions; lymphomas and other malignancies have been seen in patients treated with baricitinib or upadacitinib.  Patients who are current or past smokers are at additional increased risk of malignancies.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including ruxolitinib, pacritinib, and fedratinib.  Before starting or continuing therapy, the benefits and risks for the individual patient should be considered, especially in patients with a known malignancy (other than successfully treated nonmelanoma skin cancer), patients who develop a malignancy during therapy, and patients who are current or past smokers.  Periodic skin examination is recommended for patients who are at increased risk for skin cancer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24700, 31767, 'Baricitinib', 'Neoplasms', 'Malignancies (including lymphomas and solid tumors) have been reported in patients treated with tofacitinib and other Janus kinase (JAK) inhibitors used to treat inflammatory conditions; lymphomas and other malignancies have been seen in patients treated with baricitinib or upadacitinib.  Patients who are current or past smokers are at additional increased risk of malignancies.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including ruxolitinib, pacritinib, and fedratinib.  Before starting or continuing therapy, the benefits and risks for the individual patient should be considered, especially in patients with a known malignancy (other than successfully treated nonmelanoma skin cancer), patients who develop a malignancy during therapy, and patients who are current or past smokers.  Periodic skin examination is recommended for patients who are at increased risk for skin cancer.', '3', '', 'DDInter', 0);
